Prolactin (PRL)-secreting pituitary adenomas are the most common functioning pituitary tumors. Medical treatment with dopamine agonists is the therapy of choice for macroprolactinomas (≥10 mm). Withdrawal of bromocriptine after weeks or months of uninterrupted therapy has been associated with rapid tumor re-expansion as evidenced by x-ray and CT scanning of the pituitary region. We report a patient with a giant macroprolactinoma who had a dramatic response to bromocriptine (tumor volume shrinkage of 53% within a month) but rapid re-expansion to its original dimensions one week after discontinuation of bromocriptine. To our knowledge, this is the first time that the rapid shrinkage/re-expansion of a macroprolactinoma has been documented with...
Five patients with PRL-secreting macroadenoma and nine patients with PRL-secreting microadenoma or i...
BACKGROUND: Whether the withdrawal of treatment in patients with nontumoral hyperprolactinemia, micr...
A new long-acting repeatable injectable form of bromocriptine, (Parlodel LAR, Sandoz, Basle, Switzer...
Abstract. Prolactin (PRL)-secreting pituitary adenomas are the most common functioning pituitary tum...
PURPOSE: To study the changes in macroprolactinomas during long-term bromocriptine therapy by means ...
A 48-year-old man was diagnosed with a large macroprolactinoma in 1982 treated with surgery, adjuvan...
Fifty-one patients with hyperprolactinaemia (23 with macroadenoma, 23 with microadenoma, and five wi...
Macroprolactinomas will usually shrink with dopamine agonist therapy, often to within the pituitary ...
To investigate whether previous treatment with bromocriptine (BRC) or quinagolide (CV) impairs a sub...
Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. The...
Copyright © 2013 Atanaska Elenkova et al. is is an open access article distributed under the Creativ...
To investigate whether previous treatment with bromocriptine (BRC) or quinagolide (CV) impairs a sub...
A 45-year-old man was admitted in our department with complaints of severe headache for over 6 month...
The aim of the present study was to investigate the effect of a new galenic injectable form of bromo...
Five patients with PRL-secreting macroadenoma and nine patients with PRL-secreting microadenoma or i...
BACKGROUND: Whether the withdrawal of treatment in patients with nontumoral hyperprolactinemia, micr...
A new long-acting repeatable injectable form of bromocriptine, (Parlodel LAR, Sandoz, Basle, Switzer...
Abstract. Prolactin (PRL)-secreting pituitary adenomas are the most common functioning pituitary tum...
PURPOSE: To study the changes in macroprolactinomas during long-term bromocriptine therapy by means ...
A 48-year-old man was diagnosed with a large macroprolactinoma in 1982 treated with surgery, adjuvan...
Fifty-one patients with hyperprolactinaemia (23 with macroadenoma, 23 with microadenoma, and five wi...
Macroprolactinomas will usually shrink with dopamine agonist therapy, often to within the pituitary ...
To investigate whether previous treatment with bromocriptine (BRC) or quinagolide (CV) impairs a sub...
Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. The...
Copyright © 2013 Atanaska Elenkova et al. is is an open access article distributed under the Creativ...
To investigate whether previous treatment with bromocriptine (BRC) or quinagolide (CV) impairs a sub...
A 45-year-old man was admitted in our department with complaints of severe headache for over 6 month...
The aim of the present study was to investigate the effect of a new galenic injectable form of bromo...
Five patients with PRL-secreting macroadenoma and nine patients with PRL-secreting microadenoma or i...
BACKGROUND: Whether the withdrawal of treatment in patients with nontumoral hyperprolactinemia, micr...
A new long-acting repeatable injectable form of bromocriptine, (Parlodel LAR, Sandoz, Basle, Switzer...